TransMedics Group (NASDAQ:TMDX – Get Rating) had its target price raised by research analysts at Cowen from $28.00 to $35.00 in a research note issued to investors on Wednesday, The Fly reports. Cowen’s target price would suggest a potential upside of 60.04% from the company’s previous close.
A number of other equities research analysts have also recently weighed in on the company. Canaccord Genuity Group upped their price target on TransMedics Group from $38.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, March 17th. Morgan Stanley lowered their price target on TransMedics Group from $22.00 to $15.00 and set an “equal weight” rating on the stock in a report on Friday, February 25th. JPMorgan Chase & Co. lowered their price target on TransMedics Group from $20.00 to $12.00 in a report on Thursday, February 24th. Zacks Investment Research cut TransMedics Group from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. Finally, Canaccord Genuity Group increased their target price on TransMedics Group from $38.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, March 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $31.29.
